[Absolute risk for fracture and WHO guideline. Selection of drugs for the prevention of fractures in postmenopausal women].
It is crucial to select drugs for the prevention of fracture in postmenopausal osteoporosis. In early postmenopausal women with climacteric symptoms hormone replacement therapy (HRT) would be a first choice. Selective estrogen receptor modulator (SERM) could be prescribed in postmenopausal women who had been treated with HRT. Osteoporotic women with high risk of future fractures would be administered bisphosphonates. It is highly recommended that the doctor's decision on the drug (s) for each patient with osteoporosis could be made after obtaining the informed consent.
Gorai
Itsuo
I
International University of Health and Welfare Atami Hospital, Department of Obstetrics and Gynecology.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007258:Informed Consent; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D020845:Selective Estrogen Receptor Modulators